Prudentia’s AI-powered technology accelerates investment in breakthrough therapies that change the world.
I. Empowering biopharma to accelerate drug pipelines, maximize return on investment, and achieve clinical and commercial success for greater patient impact.
II. Enabling investors and biopharma to effectively position and showcase asset value during portfolio strategy planning and dealmaking.
III. Equipping investors with data-driven insights to optimize capital allocation in drug asset transactions.
Our Offerings
Real-time data driven simulation and scenario planning to optimize asset valuation for deal terms and enable speed to decision with increased deal throughput.
Rapid AI-powered synthesis of dataroom into an asset assessment framework enables comparison and contextualization with public and proprietary data and benchmarks to determine asset risks and value drivers.
AI-guided product profiles and asset valuations to guide portfolio strategy and decision making.
A concise and prioritized review of risks and opportunities for drug asset staging for emerging biotech and pharma.
Prudentia Prism
Prudentia Pinnacle
Prudentia Predict
Prudentia Pulse
Prudentia Pulse
A concise and prioritized review of risks and opportunities for drug asset staging for Biotechs.
Prudentia Prism
Rapid AI-powered synthesis of data room into an asset assessment framework enables comparison and contextualization with public and proprietary data and benchmarks to determine asset risks and value drivers.
Prudentia Predict
AI-Guided product profiles and asset valuations to guide portfolio strategy and decision making.
Prudentia Delta
Real-time data driven simulation and scenario planning to optimize asset valuation for deal terms and enable speed to decision with increased deal throughput.
Traceable AI
Evidence-based insights
Transparent and explainable AI
Expert in the Loop
Human expertise is directly integrated with AI insights
Security
Customer-level data isolation
Advanced data encryption
Granular access control
Enterprise Scalable
Supports large teams and workflows
Fast, reliable performance at scale
The Challenge Facing Our Industry
Scientific due diligence is manual, multidisciplinary, complex, resource intensive and has persistent disconnect between scientific potential, clinical reality and financial valuation.
Why Prudentia Sciences
Prudentia Sciences is the operating system for life sciences deal-making.
Expand capacity and resources to review more deals.
Improve collaboration with domain experts across R&D, clinical operations, and commercials across an organization.
Understand and maximize value drivers for assets.
Allocate capital efficiently by leveraging detailed insights.
Produce term sheets faster to analyze and close deals quickly.
Access industry experts and analytics at any time to evaluate the best investments.
DIFFERENTIATOR
“Our platform is designed to unlock the full potential of drug development and commercialization, ensuring that every dollar spent is optimized for impact.”
Throughput
Speed
Prudent Capital Allocation
Built for You
By leveraging human expertise with an AI-powered platform, Prudentia Sciences provides an adaptable system customized to your needs to support investment or allocation opportunities.
PHARMA
CEO & CFO
Allocate capital and optimize the value of your pipeline with internal assets and assets for licensing and M&A.
Research and Development
Deploy your team effectively to due diligence projects.
Business Development & Licensing
Accelerate the throughput of the deal pipeline and stage an asset for sale.
BIOTECH
Scientific Founders
Clarify asset value, risks, and readiness for investors.
Business Development Lead
Strengthen partner pitches with credible, data-driven valuations and asset staging.
Investors
VC & PE
Find the diamond in the rough through an accelerated process connecting diligence and valuation.
Hedge Funds
Quickly identify the alpha of mispriced assets in the marketplace.
Use Cases
Throughput: Screen the Market for the Next Big Opportunity
Throughput: Screen the Market for the Next Big Opportunity
E.g. A Pharma is seeking to expand cardiometabolic portfolio. Head of BD&L aims to identify and qualify assets for acquisition or licensing that will grow R&D pipeline.
E.g. A Pharma plans to invest/acquire approximately $750M in Phase II schizophrenia asset. Head of BD&L aim to do clinical and commercial diligence to achieve maximum Net Present Value (NPV).
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device, including to enhance site navigation and analyze site usage. More info
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device, including to enhance site navigation and analyze site usage. More info